NCT03056612已完成不适用
Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study
Jonel Trebicka45 个研究点 分布在 14 个国家目标入组 1,314 人开始时间: 2017年3月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,314
- 试验地点
- 45
- 主要终点
- Number of patients developing ACLF within 12 weeks and severity of ACLF development
研究概览
简要总结
The aim of this study is to assess prospectively the critical period prior to the development of Acute-on-Chronic Liver Failure (ACLF) (1), to uncover mechanistic and pathophysiological processes associated with the development and clinical course of ACLF (2) and to identify the precipitating events of ACLF (3).
详细描述
- This International-European, investigator-initiated, multicenter, prospective, observational study will be performed in centers that belong to the European Foundation for the Study of Chronic Liver failure (EF-CLIF)-European Association for Study of the Liver (EASL)-EASL-CLIF Consortium.
- The population of patients would include ca. 1,200 cirrhotic patients over a twelve-months period. These patients will be admitted/referred to the study center because of acute decompensation (AD) of cirrhosis (ascites, overt encephalopathy, GI-hemorrhage, new onset of non-obstructive jaundice and/or bacterial infections), without ACLF (as defined according to the Canonic study ) at hospitalization.
- After the enrolment visit, the patients will be stratified into two groups: Group 1 patients with high risk of ACLF development (CLIF-C AD score ≥ 50) and in Group 2 patients with low risk of ACLF (CLIF-C AD score <50). The whole cohort will be followed for 3 months, while Group 1 will be followed more closely. Development of ACLF is an end-point and in this case a final visit 7-10 days after ACLF development is planned. Data on liver transplantation, mortality and causes of mortality 3 months, 6 months and 12 months will be collected in the whole cohort.
- Prospective collection of biological material and performance of ancillary studies investigating predictors for development and pathogenesis of ACLF.
Specific goals of the study:
- To identify early clinical predictors, biomarkers, mechanisms and precipitating events during the critical period prior to and involved in the development and clinical course of ACLF (with special emphasis to medical trajectory and drug history) in patients admitted/referred to study center with acute decompensation of cirrhosis (ascites, GI-hemorrhage, overt encephalopathy, new onset of non-obstructive jaundice and/or bacterial infections) and the chronological relationship of the events with occurrence and dynamics of ACLF development.
- To develop a score predicting ACLF development (CLIF-PREDICT score) and assess 28-day, 90-day, 6-month and 1-year all-cause mortality in cirrhotic patients with acute AD, but without ACLF.
- To serve as a core (hub) study for prospective ancillary studies regarding diagnosis, prognosis and pathogenesis of AD and ACLF.
Main endpoints
- Assessment of the critical period prior to ACLF development
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patients admitted/referred to study center with AD of cirrhosis (ascites, overt encephalopathy, new onset of non-obstructive jaundice, GI-hemorrhage and/or bacterial infections), but without ACLF (as defined according to the CANONIC study) at study inclusion.
排除标准
- •Presence of ACLF at inclusion;
- •Age <18 years;
- •Patients with acute or subacute liver failure without underlying cirrhosis;
- •Patients with cirrhosis who develop decompensation in the postoperative period following partial hepatectomy;
- •Evidence of current malignancy except for non-melanocytic skin cancer and hepatocellular carcinoma within Milan criteria;
- •Presence or history of severe extra-hepatic diseases (e.g., chronic renal failure requiring hemodialysis, severe heart disease (NYHA > II); severe chronic pulmonary disease (GOLD > III), severe neurological and psychiatric disorders);
- •HIV-positive patients
- •Previous liver or other transplantation
- •Admission/referral of more than 72 hours before inclusion
- •Patients who decline to participate or who cannot provide prior written informed consent and when there is documented evidence that the patient has no legal surrogate decision maker and it appears unlikely that the patient will regain consciousness or sufficient ability to provide delayed informed consent;
- •Physician´s denial (e.g. the investigator considers that the patient will not follow the protocol scheduled).
结局指标
主要结局
Number of patients developing ACLF within 12 weeks and severity of ACLF development
时间窗: 12 weeks
* Characterization of mechanisms responsible for ACLF development * Predictors of clinical course dynamics of ACLF evolution and mortality. * Identification and role of precipitating events for ACLF development.
次要结局
- Score to PREDICT ACLF(12 weeks)
研究者
Jonel Trebicka
Principal Investigator EFCLIF
European Foundation for Study of Chronic Liver Failure
研究点 (45)
Loading locations...
相似试验
招募中
不适用
Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver DiseasePortal HypertensionSurgeryNon-Cirrhotic Portal HypertensionLiver CirrhosisAcute-On-Chronic Liver FailureNCT04578301University Hospital, Bonn200
已完成
不适用
Nomogram Analysis for HBV Related Acute-on-chronic Liver FailureLiver FailureNCT03992898Sun Yat-sen University2,739
已完成
不适用
Retrospective study to identify prognostic factor for the patients with acute liver injuryAcute liver injuryJPRN-UMIN000041965Iwate medical university312
尚未招募
不适用
Prognostic Significance of Acute Change in Liver and Splenic Stiffness in Patients of Acute on Chronic Liver FailureAcute on Chronic Liver FailureNCT06069284Institute of Liver and Biliary Sciences, India200
已完成
不适用
Unknown Cause of Acute Liver FailureUnknown EtiologyLiver FailureNCT02041637Assistance Publique - Hôpitaux de Paris72